一支童颜针，卖了14亿

Core Viewpoint - The article discusses the acquisition of South Korean company REGEN Biotech, Inc. by Aimeike, highlighting the strategic importance of this move in expanding Aimeike's presence in the aesthetic medicine market and its internationalization efforts [4][11]. Summary by Sections Acquisition Details - Aimeike announced it has acquired 85% of REGEN for $190 million (approximately 1.386 billion RMB), with the total valuation of REGEN at about 1.597 billion RMB [6][5]. - Following the acquisition, Aimeike will hold a 59.5% stake in REGEN, which will become a subsidiary [6][7]. Product Popularity - REGEN's product, AestheFill, known as the "childlike needle," is highly popular in the aesthetic medicine sector, with a single injection priced over 10,000 RMB. It sold around 20,000 units within two months of its domestic launch in 2024 [4][6][7]. - The product is primarily targeted at high-net-worth individuals aged 35 to 50, often referred to as "noblewomen's needles" due to the high cost and repeat usage required [6][7]. Financial Performance - REGEN reported a revenue of 15.1 billion KRW (approximately 80 million RMB) and a net profit of 9.2 billion KRW (around 50 million RMB) in 2023 [7]. - The acquisition is characterized as a high-premium purchase, with an appreciation of 278.1 billion KRW and a premium rate of 1344.12% [7]. Strategic Implications - This acquisition marks Aimeike's first significant cross-border merger since its IPO, indicating a strategic shift towards international expansion and strengthening its market position in aesthetic injection products [10][11]. - Aimeike plans to acquire the remaining 15% of REGEN after 18 months, further consolidating its control over the company [8][11]. Industry Context - The article notes a trend of increasing mergers and acquisitions among listed companies in China, driven by the need to enhance growth and competitiveness in the face of external pressures [11][12]. - Other companies in the industry, such as Huaxi Biological, have also engaged in acquisitions to expand their product lines, indicating a broader movement within the sector [11][12].